The tumor 1 (70% tumor content) had following mutations: KRAS p.G13D (allelic fraction (AF) = 35.27%), APC p.R283*(AF = 32.94%) and PIK3CA p.E545K(AF = 4.34%). This evidence concerns the gene KRAS and neoplasm.